619 related articles for article (PubMed ID: 24061039)
21. Targeted therapies for gastric cancer: current status.
Yoong J; Michael M; Leong T
Drugs; 2011 Jul; 71(11):1367-84. PubMed ID: 21812503
[TBL] [Abstract][Full Text] [Related]
22. Molecular targeted treatment and drug delivery system for gastric cancer.
Jiang L; Gong X; Liao W; Lv N; Yan R
J Cancer Res Clin Oncol; 2021 Apr; 147(4):973-986. PubMed ID: 33550445
[TBL] [Abstract][Full Text] [Related]
23. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
24. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
[TBL] [Abstract][Full Text] [Related]
25. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH
BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
27. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.
Liu Y; Chen S; Xue R; Zhao J; Di M
Biochem Biophys Res Commun; 2016 Feb; 470(2):350-355. PubMed ID: 26780727
[TBL] [Abstract][Full Text] [Related]
28. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
29. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
30. Molecular targeted therapy for the treatment of gastric cancer.
Xu W; Yang Z; Lu N
J Exp Clin Cancer Res; 2016 Jan; 35():1. PubMed ID: 26728266
[TBL] [Abstract][Full Text] [Related]
31. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
32. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
33. New targeted therapies for gastric cancer.
Asaoka Y; Ikenoue T; Koike K
Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
[TBL] [Abstract][Full Text] [Related]
34. Targeting receptor tyrosine kinases in gastric cancer.
Morishita A; Gong J; Masaki T
World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
[TBL] [Abstract][Full Text] [Related]
35. Management of advanced gastric cancer.
Price TJ; Shapiro JD; Segelov E; Karapetis CS; Pavlakis N; Van Cutsem E; Shah MA; Kang YK; Tebbutt NC
Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):199-208; quiz 209. PubMed ID: 22375525
[TBL] [Abstract][Full Text] [Related]
36. How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
Corso S; Giordano S
Trends Mol Med; 2016 Jul; 22(7):534-544. PubMed ID: 27260398
[TBL] [Abstract][Full Text] [Related]
37. Incorporation of targeted agents in the management of patients with advanced gastric cancer.
Pentheroudakis G; Stoyianni A
Curr Med Chem; 2011; 18(11):1629-39. PubMed ID: 21428884
[TBL] [Abstract][Full Text] [Related]
38. High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.
Labots M; Buffart TE; Haan JC; van Grieken NC; Tijssen M; van de Velde CJ; Grabsch HI; Ylstra B; Carvalho B; Fijneman RJ; Verheul HM; Meijer GA
Cell Oncol (Dordr); 2014 Feb; 37(1):41-52. PubMed ID: 24379144
[TBL] [Abstract][Full Text] [Related]
39. Molecular-targeted first-line therapy for advanced gastric cancer.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490
[TBL] [Abstract][Full Text] [Related]
40. Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?
Kataoka K; Deleersnijder A; Lordick F
Eur J Surg Oncol; 2017 Oct; 43(10):1835-1845. PubMed ID: 28888797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
